Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

Axsome Therapeutics (AXSM) stock gains as solriamfetol, its experimental drug for ADHD succeeds in a Phase 3 trial. Read more ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

In trading on Tuesday, shares of Axsome Therapeutics Inc (Symbol: AXSM) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $107 per share. By ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM). Shares have lost about 0.8% in that time frame, outperforming the S&P 500. Will the recent negative trend ...

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities ...